You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMinocycline
Accession NumberDB01017  (APRD00547)
TypeSmall Molecule
GroupsApproved, Investigational
Description

A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. [PubChem]

Structure
Thumb
Synonyms
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
7-Dimethylamino-6-demethyl-6-deoxytetracycline
Minociclina
Minociclinum
Minocyclin
Minocyclinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arestinpowder1 mg/1oralOra Pharma, Inc.2011-03-21Not applicableUs
Arestin Microspherespowder (extended release)1 mgsubgingivalOrapharma Inc2008-07-27Not applicableCanada
Dom-minocycline Capsulescapsule100 mgoralDominion Pharmacal2000-11-24Not applicableCanada
Dom-minocycline Capsulescapsule50 mgoralDominion Pharmacal2000-11-24Not applicableCanada
Enca 100mgcapsule100 mgoralPrempharm Inc2003-10-032009-08-05Canada
Enca 50mgcapsule50 mgoralPrempharm Inc2003-10-032009-08-05Canada
Minocincapsule, coated pellets75 mg/1oralOnset Dermatologics LLC1990-05-31Not applicableUs
Minocincapsule50 mgoralGlaxosmithkline Inc1996-10-252012-12-10Canada
MinocinkitOnset Dermatologics, LLC2013-06-172016-01-31Us
Minocincapsule100 mgoralGlaxosmithkline Inc1996-10-252012-12-10Canada
MinocinkitOnset Dermatologics, LLC2013-06-172016-01-31Us
Minocincapsule, coated pellets50 mg/1oralOnset Dermatologics LLC1990-05-31Not applicableUs
Minocininjection100 mg/1intravenousThe Medicines Company2013-04-19Not applicableUs
Minocincapsule, coated pellets100 mg/1oralOnset Dermatologics LLC1990-05-31Not applicableUs
Minocininjection100 mg/1intravenousRempex Pharmaceuticals, Inc2013-04-19Not applicableUs
Minocin Cap 100mgcapsule100 mgoralLederle Cyanamid Canada Inc.1971-12-311997-08-14Canada
Minocin Cap 50mgcapsule50 mgoralLederle Cyanamid Canada Inc.1974-12-311997-08-14Canada
Minocin Kitcapsule, coated pellets50 mg/1oralTriax Pharmaceuticals, LLC2007-09-012016-01-31Us
Minocin Kitcapsule, coated pellets100 mg/1oralTriax Pharmaceuticals, LLC2007-09-012016-01-31Us
Minocyclinecapsule100 mgoralSanis Health Inc2010-02-25Not applicableCanada
Minocyclinecapsule50 mgoralSanis Health Inc2010-02-25Not applicableCanada
Minocyclinecapsule100 mgoralIvax Pharmaceuticals Incorporated2000-01-24Not applicableCanada
Minocycline-100capsule100 mgoralPro Doc Limitee1995-12-31Not applicableCanada
Minocycline-50capsule50 mgoralPro Doc Limitee1995-12-31Not applicableCanada
Mylan-minocyclinecapsule100 mgoralMylan Pharmaceuticals Ulc1997-02-21Not applicableCanada
Mylan-minocyclinecapsule50 mgoralMylan Pharmaceuticals Ulc1997-02-21Not applicableCanada
Nu-minocyclinecapsule100 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-minocyclinecapsule50 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-minocyclinecapsule100 mgoralPharmel Inc2009-02-10Not applicableCanada
PHL-minocyclinecapsule50 mgoralPharmel Inc2009-02-10Not applicableCanada
PMS-minocyclinecapsule50 mgoralPharmascience Inc2007-10-01Not applicableCanada
PMS-minocyclinecapsule100 mgoralPharmascience Inc2000-06-12Not applicableCanada
PMS-minocyclinecapsule50 mgoralPharmascience Inc2000-06-12Not applicableCanada
PMS-minocyclinecapsule100 mgoralPharmascience Inc2007-10-01Not applicableCanada
Ran-minocyclinecapsule100 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-minocyclinecapsule50 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ratio-minocyclinecapsule100 mgoralRatiopharm Inc Division Of Teva Canada Limited1993-12-312014-09-19Canada
Ratio-minocyclinecapsule50 mgoralRatiopharm Inc Division Of Teva Canada Limited1993-12-312014-09-19Canada
Riva-minocyclinecapsule100 mgoralLaboratoire Riva Inc2000-05-232013-07-31Canada
Riva-minocycline 50 mgcapsule50 mgoralLaboratoire Riva Inc2000-05-232013-07-31Canada
Sandoz Minocyclinecapsule100 mgoralSandoz Canada Incorporated2000-11-06Not applicableCanada
Sandoz Minocyclinecapsule50 mgoralSandoz Canada Incorporated2000-11-06Not applicableCanada
Solodyntablet, film coated, extended release105 mg/1oralMedicis Pharmaceutical Corp.2010-09-27Not applicableUs
Solodyntablet, film coated, extended release80 mg/1oralMedicis Pharmaceutical Corp.2010-09-27Not applicableUs
Solodyntablet, film coated, extended release55 mg/1oralMedicis Pharmaceutical Corp.2010-09-27Not applicableUs
Solodyntablet, film coated, extended release115 mg/1oralMedicis Pharmaceutical Corp.2009-07-23Not applicableUs
Solodyntablet, film coated, extended release65 mg/1oralMedicis Pharmaceutical Corp.2009-07-23Not applicableUs
Solodyntablet, film coated, extended release80 mg/1oralPhysicians Total Care, Inc.2011-07-18Not applicableUs
Teva-minocyclinecapsule100 mgoralTeva Canada Limited1994-12-31Not applicableCanada
Teva-minocyclinecapsule50 mgoralTeva Canada Limited1994-12-31Not applicableCanada
Ximinocapsule, extended release45 mg/1oralRanbaxy Laboratories Inc.2012-09-01Not applicableUs
Ximinocapsule, extended release135 mg/1oralRanbaxy Laboratories Inc.2012-09-01Not applicableUs
Ximinocapsule, extended release90 mg/1oralRanbaxy Laboratories Inc.2012-09-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-minocycline Cap 100mgcapsule100 mgoralApotex Inc1994-12-31Not applicableCanada
Apo-minocycline Cap 50mgcapsule50 mgoralApotex Inc1994-12-31Not applicableCanada
Dynacintablet100 mg/1oralPar Pharmaceutical, Inc.2011-06-20Not applicableUs
Dynacintablet75 mg/1oralPar Pharmaceutical, Inc.2011-06-20Not applicableUs
Dynacintablet50 mg/1oralPar Pharmaceutical, Inc.2011-06-20Not applicableUs
Minocyclinetablet, film coated75 mg/1oralSun Pharmaceuticals Industries Inc.2016-01-29Not applicableUs
Minocyclinetablet, film coated50 mg/1oralSun Pharmaceuticals Industries Inc.2016-01-29Not applicableUs
Minocyclinetablet100 mg/1oralPar Pharmaceutical, Inc.2003-04-16Not applicableUs
Minocyclinetablet75 mg/1oralPar Pharmaceutical, Inc.2003-04-16Not applicableUs
Minocyclinetablet50 mg/1oralPar Pharmaceutical, Inc.2003-04-16Not applicableUs
Minocyclinetablet100 mg/1oralAv Kare, Inc.2015-05-08Not applicableUs
Minocyclinetablet50 mg/1oralAv Kare, Inc.2015-05-08Not applicableUs
Minocyclinetablet, film coated100 mg/1oralSun Pharmaceuticals Industries Inc.2016-01-29Not applicableUs
Minocycline Hydrochloridecapsule75 mg/1oralbryant ranch prepack1999-06-10Not applicableUs
Minocycline Hydrochloridecapsule75 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.1999-03-23Not applicableUs
Minocycline Hydrochloridecapsule75 mg/1oralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralTeva Pharmaceuticals USA Inc1992-05-01Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralPd Rx Pharmaceuticals, Inc.1991-12-30Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralPhysicians Total Care, Inc.2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralAv Pak2015-01-28Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-08Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralREMEDYREPACK INC.2011-03-30Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralRebel Distributors Corp.2000-11-30Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralbryant ranch prepack2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralProficient Rx LP2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralClinical Solutions Wholesale, Llc2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralAmerican Health Packaging2012-09-30Not applicableUs
Minocycline Hydrochloridetablet, extended release135 mg/1oralSandoz Inc2009-08-13Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralPd Rx Pharmaceuticals, Inc.1991-12-30Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralPhysicians Total Care, Inc.2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralLake Erie Medical DBA Quality Care Products LLC1991-12-30Not applicableUs
Minocycline Hydrochloridetablet, film coated, extended release135 mg/1oralPru Gen Pharmaceuticals2012-11-19Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralbryant ranch prepack2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralProficient Rx LP2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralAmerican Health Packaging2008-08-272015-12-29Us
Minocycline Hydrochloridecapsule100 mg/1oralDispensing Solution, Inc.1991-12-30Not applicableUs
Minocycline Hydrochloridetablet, extended release90 mg/1oralSandoz Inc2009-08-13Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.1999-03-23Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralCardinal Health1992-05-01Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralREMEDYREPACK INC.2013-07-08Not applicableUs
Minocycline Hydrochloridetablet, film coated, extended release90 mg/1oralPru Gen Pharmaceuticals2012-11-19Not applicableUs
Minocycline Hydrochloridetablet, film coated100 mg/1oralRanbaxy Pharmaceuticals Inc.2004-06-29Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralDIRECT RX2015-11-30Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralPreferred Pharmaceuticals, Inc.2000-12-22Not applicableUs
Minocycline Hydrochloridetablet, film coated, extended release135 mg/1oralAurobindo Pharma Limited2012-11-19Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralAv Kare, Inc.2011-07-26Not applicableUs
Minocycline Hydrochloridetablet, extended release45 mg/1oralSandoz Inc2009-08-13Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.1999-03-23Not applicableUs
Minocycline Hydrochloridetablet, film coated, extended release45 mg/1oralPru Gen Pharmaceuticals2012-11-19Not applicableUs
Minocycline Hydrochloridetablet, film coated75 mg/1oralRanbaxy Pharmaceuticals Inc.2004-06-29Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralDIRECT RX2015-11-30Not applicableUs
Minocycline Hydrochloridetablet, extended release135 mg/1oralLupin Pharmaceuticals, Inc.2012-02-14Not applicableUs
Minocycline Hydrochloridetablet, film coated, extended release90 mg/1oralAurobindo Pharma Limited2012-11-19Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralDepartment Of State Health Services, Pharmacy Branch1991-12-30Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralActavis Pharma, Inc.1991-12-30Not applicableUs
Minocycline Hydrochloridetablet, extended release135 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-02-03Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralCardinal Health1991-12-30Not applicableUs
Minocycline Hydrochloridecapsule75 mg/1oralREMEDYREPACK INC.2013-06-03Not applicableUs
Minocycline Hydrochloridetablet, film coated50 mg/1oralRanbaxy Pharmaceuticals Inc.2004-06-29Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Minocycline Hydrochloridetablet, extended release90 mg/1oralLupin Pharmaceuticals, Inc.2012-02-14Not applicableUs
Minocycline Hydrochloridetablet, film coated, extended release45 mg/1oralAurobindo Pharma Limited2012-11-19Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralSun Pharmaceutical Industries, Inc.2013-05-13Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralActavis Pharma, Inc.1991-12-30Not applicableUs
Minocycline Hydrochloridetablet100 mg/1oralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline Hydrochloridetablet, extended release90 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-02-03Not applicableUs
Minocycline Hydrochloridetablet, film coated100 mg/1oralDr. Reddy's Laboratories Limited2008-01-23Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralNorthwind Pharmaceuticals, LLC2014-08-20Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralRanbaxy Pharmaceuticals Inc.2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Minocycline Hydrochloridetablet, extended release45 mg/1oralLupin Pharmaceuticals, Inc.2012-02-14Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralAurobindo Pharma Limited2008-03-11Not applicableUs
Minocycline Hydrochloridecapsule75 mg/1oralSun Pharmaceutical Industries, Inc.2013-05-13Not applicableUs
Minocycline Hydrochloridecapsule75 mg/1oralActavis Pharma, Inc.1999-06-10Not applicableUs
Minocycline Hydrochloridetablet75 mg/1oralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline Hydrochloridetablet, extended release45 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-02-03Not applicableUs
Minocycline Hydrochloridetablet, film coated75 mg/1oralDr. Reddy's Laboratories Limited2008-01-23Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralUnit Dose Services2008-03-11Not applicableUs
Minocycline Hydrochloridecapsule75 mg/1oralRanbaxy Pharmaceuticals Inc.2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralREMEDYREPACK INC.2015-04-16Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralCarilion Materials Management1991-12-30Not applicableUs
Minocycline Hydrochloridecapsule75 mg/1oralAurobindo Pharma Limited2008-03-11Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralSun Pharmaceutical Industries, Inc.2013-05-13Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralLiberty Pharmaceuticals, Inc.2000-12-22Not applicableUs
Minocycline Hydrochloridetablet50 mg/1oralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline Hydrochloridecapsule75 mg/1oralTeva Pharmaceuticals USA Inc2004-06-30Not applicableUs
Minocycline Hydrochloridetablet, film coated50 mg/1oralDr. Reddy's Laboratories Limited2008-01-23Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralUnit Dose Services2008-03-11Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralAidarex Pharmaceuticals LLC2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralRanbaxy Pharmaceuticals Inc.2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralClinical Solutions Wholesale2008-03-11Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Minocycline Hydrochloridecapsule50 mg/1oralAurobindo Pharma Limited2008-03-11Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralKAISER FOUNDATION HOSPITALS2006-08-04Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralTeva Pharmaceuticals USA Inc1992-05-01Not applicableUs
Minocycline Hydrochloridecapsule75 mg/1oralPhysicians Total Care, Inc.2000-12-22Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralAv Pak2014-11-07Not applicableUs
Minocycline Hydrochloridecapsule100 mg/1oralAidarex Pharmaceuticals LLC2000-12-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AkneminNot Available
Apo-MinocyclineNot Available
KlinomycinNot Available
MinodermNot Available
MinomycinNot Available
MinopenNot Available
MinoxNot Available
MinozNot Available
VectrinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Minocycline hydrochloride
13614-98-7
Thumb
  • InChI Key: GLMUAFMGXXHGLU-VQAITOIOSA-N
  • Monoisotopic Mass: 493.161578
  • Average Mass: 493.94
DBSALT000721
Categories
UNIIFYY3R43WGO
CAS number10118-90-8
WeightAverage: 457.4764
Monoisotopic: 457.184900233
Chemical FormulaC23H27N3O7
InChI KeyInChIKey=DYKFCLLONBREIL-KVUCHLLUSA-N
InChI
InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1
IUPAC Name
(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
SMILES
[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassTetracyclines
Sub ClassNot Available
Direct ParentTetracyclines
Alternative Parents
Substituents
  • Tetracycline
  • Tetracene
  • Naphthacene
  • Anthracene carboxylic acid or derivatives
  • Tetralin
  • Dialkylarylamine
  • Aryl ketone
  • Aralkylamine
  • Benzenoid
  • Vinylogous acid
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Primary carboxylic acid amide
  • Polyol
  • Ketone
  • Carboxamide group
  • Enol
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by Streptococcus pneumoniae and for the treatment of asymptomatic carriers of Neisseria meningitidis.
PharmacodynamicsMinocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.
Mechanism of actionMinocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Tetracyclines like minocycline bind to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.
Related Articles
AbsorptionRapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.
Volume of distributionNot Available
Protein binding55% to 76%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life11-22 hours
ClearanceNot Available
ToxicityMinocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD50=2380 mg/kg (rat, oral), LD50=3600 mg/kg (mouse, oral)
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategorySMPDB ID
Minocycline Action PathwayDrug actionSMP00292
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7469
Blood Brain Barrier-0.9783
Caco-2 permeable+0.5711
P-glycoprotein substrateSubstrate0.7366
P-glycoprotein inhibitor INon-inhibitor0.7968
P-glycoprotein inhibitor IINon-inhibitor0.7036
Renal organic cation transporterNon-inhibitor0.9536
CYP450 2C9 substrateNon-substrate0.8145
CYP450 2D6 substrateNon-substrate0.9036
CYP450 3A4 substrateSubstrate0.6805
CYP450 1A2 substrateNon-inhibitor0.9088
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9081
CYP450 3A4 inhibitorNon-inhibitor0.9058
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7561
Ames testNon AMES toxic0.8909
CarcinogenicityNon-carcinogens0.9091
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4354 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9954
hERG inhibition (predictor II)Non-inhibitor0.6783
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Medicis pharmaceutical corp
  • Triax pharmaceuticals llc
  • Aurobindo pharma ltd
  • Impax laboratories inc
  • Ranbaxy laboratories ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Lederle laboratories div american cyanamid co
  • Orapharma inc
  • Barr laboratories inc
  • Matrix laboratories ltd
  • Sandoz inc
  • Dr reddys laboratories ltd
  • Medicis Pharmaceutical Corporation
Packagers
Dosage forms
FormRouteStrength
Capsuleoral100 mg
Capsuleoral50 mg
Powderoral1 mg/1
Powder (extended release)subgingival1 mg
Tabletoral75 mg/1
Capsule, coated pelletsoral75 mg/1
Injectionintravenous100 mg/1
Kit
Capsule, coated pelletsoral100 mg/1
Capsule, coated pelletsoral50 mg/1
Tabletoral100 mg/1
Tabletoral50 mg/1
Capsuleoral100 mg/1
Capsuleoral50 mg/1
Capsuleoral75 mg/1
Tablet, extended releaseoral135 mg/1
Tablet, extended releaseoral45 mg/1
Tablet, extended releaseoral90 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral50 mg/1
Tablet, film coatedoral75 mg/1
Tablet, film coated, extended releaseoral135 mg/1
Tablet, film coated, extended releaseoral45 mg/1
Tablet, film coated, extended releaseoral90 mg/1
Tablet, film coated, extended releaseoral105 mg/1
Tablet, film coated, extended releaseoral115 mg/1
Tablet, film coated, extended releaseoral55 mg/1
Tablet, film coated, extended releaseoral65 mg/1
Tablet, film coated, extended releaseoral80 mg/1
Capsule, extended releaseoral135 mg/1
Capsule, extended releaseoral45 mg/1
Capsule, extended releaseoral90 mg/1
Prices
Unit descriptionCostUnit
Minocin PAC 100 mg Kit Box695.5USD box
Minocin kit 100 mg combo668.17USD kit
Minocin kit 50 mg combo334.78USD kit
Minocin 100 mg vial59.64USD vial
Arestin 1 mg microsphere30.0USD each
Solodyn 135 mg 24 Hour tablet24.89USD tablet
Solodyn 45 mg 24 Hour tablet24.89USD tablet
Solodyn 65 mg 24 Hour tablet24.89USD tablet
Solodyn 90 mg 24 Hour tablet24.89USD tablet
Solodyn er 115 mg tablet23.93USD tablet
Solodyn er 135 mg tablet23.93USD tablet
Solodyn er 45 mg tablet23.93USD tablet
Solodyn er 65 mg tablet23.93USD tablet
Solodyn er 90 mg tablet23.93USD tablet
Minocycline hcl powder21.0USD g
Minocycline HCl 135 mg 24 Hour tablet19.21USD tablet
Minocycline HCl 45 mg 24 Hour tablet19.21USD tablet
Dynacin 100 mg tablet13.37USD tablet
Dynacin 75 mg tablet13.12USD tablet
Minocin 100 mg capsule12.05USD capsule
Minocin 100 mg pelletized cap11.11USD pellet
Dynacin 50 mg tablet8.76USD tablet
Dynacin 75 mg capsule7.15USD capsule
Minocycline hcl 100 mg tablet6.15USD tablet
Minocin 50 mg pelletized cap5.56USD pellet
Minocin 50 mg capsule5.24USD capsule
Minocycline hcl 75 mg tablet5.14USD tablet
Dynacin 50 mg capsule3.85USD capsule
Minocycline HCl 100 mg capsule3.53USD capsule
Minocycline hcl 50 mg tablet3.5USD tablet
Minocycline HCl 75 mg capsule2.06USD capsule
Minocycline 75 mg capsule1.98USD capsule
Minocycline HCl 50 mg capsule1.77USD capsule
Minocin 100 mg Capsule1.34USD capsule
Apo-Minocycline 100 mg Capsule1.08USD capsule
Minocycline 100 mg Capsule1.08USD capsule
Mylan-Minocycline 100 mg Capsule1.08USD capsule
Novo-Minocycline 100 mg Capsule1.08USD capsule
Pms-Minocycline 100 mg Capsule1.08USD capsule
Ratio-Minocycline 100 mg Capsule1.08USD capsule
Sandoz Minocycline 100 mg Capsule1.08USD capsule
Minocin 50 mg Capsule0.69USD capsule
Apo-Minocycline 50 mg Capsule0.56USD capsule
Minocycline 50 mg Capsule0.56USD capsule
Mylan-Minocycline 50 mg Capsule0.56USD capsule
Novo-Minocycline 50 mg Capsule0.56USD capsule
Pms-Minocycline 50 mg Capsule0.56USD capsule
Ratio-Minocycline 50 mg Capsule0.56USD capsule
Sandoz Minocycline 50 mg Capsule0.56USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1330533 No1994-07-052011-07-05Canada
US5908838 No1998-02-192018-02-19Us
US6682348 No2002-03-292022-03-29Us
US7541347 No2007-04-022027-04-02Us
US7544373 No2007-04-022027-04-02Us
US7699609 No2002-03-292022-03-29Us
US7790705 No2005-06-242025-06-24Us
US7919483 No2007-03-072027-03-07Us
US8252776 No2005-06-242025-06-24Us
US8268804 No2005-06-242025-06-24Us
US8722650 No2005-06-242025-06-24Us
US9084802 No2011-05-122031-05-12Us
US9192615 No2011-11-172031-11-17Us
US9278105 No2011-05-122031-05-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility5.2E+004 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.05SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility3.07 mg/mLALOGPS
logP-0.03ALOGPS
logP-3.3ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)-2.3ChemAxon
pKa (Strongest Basic)8.25ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area164.63 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity122.54 m3·mol-1ChemAxon
Polarizability45.9 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Zita Mendes, Jose Rafael Antunes, Susana Marto, William Heggie, “Crystalline Minocycline Base and Processes for its Preparation.” U.S. Patent US20100286417, issued November 11, 2010.

US20100286417
General References
  1. Gough A, Chapman S, Wagstaff K, Emery P, Elias E: Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996 Jan 20;312(7024):169-72. [PubMed:8563540 ]
  2. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. [PubMed:10888929 ]
  3. Tikka TM, Koistinaho JE: Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol. 2001 Jun 15;166(12):7527-33. [PubMed:11390507 ]
  4. Nirmalananthan N, Greensmith L: Amyotrophic lateral sclerosis: recent advances and future therapies. Curr Opin Neurol. 2005 Dec;18(6):712-9. [PubMed:16280684 ]
  5. Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4. [PubMed:15371729 ]
  6. Link [Link]
External Links
ATC CodesA01AB23J01AA08
AHFS Codes
  • 08:12.24
PDB Entries
FDA labelDownload (3.02 MB)
MSDSDownload (73.6 KB)
Interactions
Drug Interactions
Drug
AlfentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.
AlprazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmdinocillinThe therapeutic efficacy of Amdinocillin can be decreased when used in combination with Minocycline.
AmitriptylineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
AmobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
AmoxapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
AmoxicillinThe therapeutic efficacy of Amoxicillin can be decreased when used in combination with Minocycline.
AmpicillinThe therapeutic efficacy of Ampicillin can be decreased when used in combination with Minocycline.
AripiprazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
AsenapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Asenapine.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Minocycline.
Atracurium besylateMinocycline may increase the neuromuscular blocking activities of Atracurium besylate.
AzelastineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzidocillinThe therapeutic efficacy of Azidocillin can be decreased when used in combination with Minocycline.
AzlocillinThe therapeutic efficacy of Azlocillin can be decreased when used in combination with Minocycline.
BacampicillinThe therapeutic efficacy of Bacampicillin can be decreased when used in combination with Minocycline.
BaclofenMinocycline may increase the central nervous system depressant (CNS depressant) activities of Baclofen.
BenzylpenicillinThe therapeutic efficacy of Benzylpenicillin can be decreased when used in combination with Minocycline.
Bismuth SubcitrateThe serum concentration of Minocycline can be decreased when it is combined with Bismuth Subcitrate.
Bismuth SubsalicylateThe serum concentration of Minocycline can be decreased when it is combined with Bismuth Subsalicylate.
BrexpiprazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
BrimonidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.
BromazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
BrompheniramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
BuprenorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
ButabarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
ButorphanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
CarbamazepineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
CarbenicillinThe therapeutic efficacy of Carbenicillin can be decreased when used in combination with Minocycline.
CarbinoxamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
CarisoprodolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
CetirizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.
ChlordiazepoxideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
ChlorphenamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.
ChlorpromazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
ChlorzoxazoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
Cisatracurium besylateMinocycline may increase the neuromuscular blocking activities of Cisatracurium besylate.
ClemastineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
ClobazamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clobazam.
ClomipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
ClonazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.
ClonidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clonidine.
ClorazepateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
CloxacillinThe therapeutic efficacy of Cloxacillin can be decreased when used in combination with Minocycline.
ClozapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
ColesevelamColesevelam can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclacillinThe therapeutic efficacy of Cyclacillin can be decreased when used in combination with Minocycline.
CyclizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
CyclobenzaprineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
CyproheptadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
DantroleneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
DesfluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
DesipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
DesloratadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
Dexchlorpheniramine maleateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dexchlorpheniramine maleate.
DiazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
DicloxacillinThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Minocycline.
DicoumarolMinocycline may increase the anticoagulant activities of Dicoumarol.
DimenhydrinateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
DiphenhydramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.
DoxepinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DoxylamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.
DroperidolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
EfavirenzMinocycline may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
EntacaponeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
EstazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
EszopicloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
EthosuximideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
EthotoinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
EzogabineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.
FelbamateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
FentanylMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
FexofenadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.
FlibanserinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
FlucloxacillinThe therapeutic efficacy of Flucloxacillin can be decreased when used in combination with Minocycline.
FlunarizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
FlupentixolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.
FluphenazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
FlurazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
FosphenytoinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
GabapentinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
gabapentin enacarbilMinocycline may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.
Gamma Hydroxybutyric AcidMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.
GuanfacineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.
HaloperidolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
HetacillinThe therapeutic efficacy of Hetacillin can be decreased when used in combination with Minocycline.
HydrocodoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydromorphoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
HydroxyzineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.
IloperidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
ImipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Iron DextranMinocycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
IsofluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.
KetamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
LamotrigineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.
LanthanumThe serum concentration of Minocycline can be decreased when it is combined with Lanthanum.
LevetiracetamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
LevocabastineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.
LevocetirizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.
LevorphanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
LoratadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Loratadine.
LorazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
LoxapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
LurasidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
MaprotilineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
MecamylamineMinocycline may increase the neuromuscular blocking activities of Mecamylamine.
MeclizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Meclizine.
MeprobamateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
MetaxaloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
MethadoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethocarbamolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
MethohexitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
MethotrimeprazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethsuximideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
MeticillinThe therapeutic efficacy of Meticillin can be decreased when used in combination with Minocycline.
MezlocillinThe therapeutic efficacy of Mezlocillin can be decreased when used in combination with Minocycline.
MidazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
MipomersenMinocycline may increase the hepatotoxic activities of Mipomersen.
MirtazapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Morphine.
NafcillinThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Minocycline.
NalbuphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
NitrazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Nitrous oxideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.
NortriptylineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
OlanzapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
OlopatadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
OrphenadrineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxacillinThe therapeutic efficacy of Oxacillin can be decreased when used in combination with Minocycline.
OxazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
OxycodoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.
OxymorphoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
PaliperidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
PancuroniumMinocycline may increase the neuromuscular blocking activities of Pancuronium.
ParaldehydeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
PentazocineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
PentobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
PerampanelMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
PerphenazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
PethidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PhenobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
PhenoxymethylpenicillinThe therapeutic efficacy of Phenoxymethylpenicillin can be decreased when used in combination with Minocycline.
PhenytoinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
Picosulfuric acidThe therapeutic efficacy of Sodium picosulfate can be decreased when used in combination with Minocycline.
PimozideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
PiperacillinThe therapeutic efficacy of Piperacillin can be decreased when used in combination with Minocycline.
PipotiazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
PivampicillinThe therapeutic efficacy of Pivampicillin can be decreased when used in combination with Minocycline.
PivmecillinamThe therapeutic efficacy of Pivmecillinam can be decreased when used in combination with Minocycline.
PizotifenMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.
PomalidomideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
PorfimerMinocycline may increase the photosensitizing activities of Porfimer.
PregabalinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
PrimidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Primidone.
ProchlorperazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
PromazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Promazine.
PromethazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
PropofolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Propofol.
ProtriptylineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
QuazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
QuetiapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
QuinaprilThe serum concentration of Minocycline can be decreased when it is combined with Quinapril.
RamelteonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
RemifentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
ReserpineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
RisperidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
RocuroniumMinocycline may increase the neuromuscular blocking activities of Rocuronium.
ScopolamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Scopolamine butylbromideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine butylbromide.
SecobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
SevofluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
Sodium oxybateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
StiripentolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.
Strontium ranelateThe serum concentration of Minocycline can be decreased when it is combined with Strontium ranelate.
SuccinylcholineMinocycline may increase the neuromuscular blocking activities of Succinylcholine.
SucralfateSucralfate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sucroferric OxyhydroxideThe serum concentration of Minocycline can be decreased when it is combined with Sucroferric Oxyhydroxide.
SufentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
SuvorexantMinocycline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TapentadolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
TasimelteonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.
TemazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
TetrabenazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.
ThalidomideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
ThiothixeneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
TiagabineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
TicarcillinThe therapeutic efficacy of Ticarcillin can be decreased when used in combination with Minocycline.
TizanidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
TolcaponeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
TopiramateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
TramadolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
TriazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
TrifluoperazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
TrimipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
TriprolidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
VecuroniumMinocycline may increase the neuromuscular blocking activities of Vecuronium.
VerteporfinMinocycline may increase the photosensitizing activities of Verteporfin.
VigabatrinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.
ZaleplonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
ZiconotideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.
ZiprasidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
ZolpidemMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZonisamideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
ZopicloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.
ZuclopenthixolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
Food Interactions
  • Calcium and iron needs increased with long term use.
  • Do not take Aluminum or magnesium antacids or supplements while on this medication.
  • Take with food.

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Trna binding
Specific Function:
The C-terminal tail plays a role in the affinity of the 30S P site for different tRNAs. Mutations that decrease this affinity are suppressed in the 70S ribosome.
Gene Name:
rpsI
Uniprot ID:
P0A7X3
Molecular Weight:
14856.105 Da
References
  1. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ: The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. [PubMed:14723559 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Translation repressor activity, nucleic acid binding
Specific Function:
One of two assembly initiator proteins for the 30S subunit, it binds directly to 16S rRNA where it nucleates assembly of the body of the 30S subunit.With S5 and S12 plays an important role in translational accuracy; many suppressors of streptomycin-dependent mutants of protein S12 are found in this protein, some but not all of which decrease translational accuracy (ram, ribosomal ambiguity muta...
Gene Name:
rpsD
Uniprot ID:
P0A7V8
Molecular Weight:
23468.915 Da
References
  1. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ: The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. [PubMed:14723559 ]
3. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
unknown
Actions
inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
modulator
General Function:
Protein domain specific binding
Specific Function:
Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells.
Gene Name:
IL1B
Uniprot ID:
P01584
Molecular Weight:
30747.7 Da
References
  1. Sadowski T, Steinmeyer J: Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes. J Rheumatol. 2001 Feb;28(2):336-40. [PubMed:11246672 ]
  2. Oringer RJ, Al-Shammari KF, Aldredge WA, Iacono VJ, Eber RM, Wang HL, Berwald B, Nejat R, Giannobile WV: Effect of locally delivered minocycline microspheres on markers of bone resorption. J Periodontol. 2002 Aug;73(8):835-42. [PubMed:12211491 ]
  3. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB: A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14014-9. [PubMed:8943052 ]
  4. Steinmeyer J, Daufeldt S, Taiwo YO: Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage. Biochem Pharmacol. 1998 Jan 1;55(1):93-100. [PubMed:9413935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Iron ion binding
Specific Function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Molecular Weight:
77982.595 Da
References
  1. Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4. [PubMed:15371729 ]
  2. Song Y, Wei EQ, Zhang WP, Ge QF, Liu JR, Wang ML, Huang XJ, Hu X, Chen Z: Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation. Brain Res. 2006 Apr 26;1085(1):57-67. Epub 2006 Mar 30. [PubMed:16574083 ]
  3. Chu LS, Fang SH, Zhou Y, Yu GL, Wang ML, Zhang WP, Wei EQ: Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. Acta Pharmacol Sin. 2007 Jun;28(6):763-72. [PubMed:17506934 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.
Gene Name:
MMP9
Uniprot ID:
P14780
Molecular Weight:
78457.51 Da
References
  1. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW: Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain. 2002 Jun;125(Pt 6):1297-308. [PubMed:12023318 ]
  2. Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC: Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol. 2005 Jan;288(1):F91-7. Epub 2004 Sep 7. [PubMed:15353401 ]
  3. Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, Opdenakker G, Koistinaho J: Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab. 2005 Apr;25(4):460-7. [PubMed:15674236 ]
  4. Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ, Lin E, Yang GY, Young WL: Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab. 2006 Sep;26(9):1157-64. Epub 2006 Jan 4. [PubMed:16395286 ]
  5. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC: Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006 Jul 17;7:56. [PubMed:16846501 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vascular endothelial growth factor receptor binding
Specific Function:
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activ...
Gene Name:
VEGFA
Uniprot ID:
P15692
Molecular Weight:
27042.205 Da
References
  1. Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, Itoh N, Tsukamoto T: Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer. 2002 Mar 4;86(5):768-73. [PubMed:11875741 ]
  2. Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang GY: Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res. 2004 Aug 20;95(4):364-71. Epub 2004 Jul 15. [PubMed:15256478 ]
  3. Rocchetti R, Talevi S, Margiotta C, Calza R, Corallini A, Possati L: Antiangiogenic drugs for chemotherapy of bladder tumours. Chemotherapy. 2005 Oct;51(6):291-9. Epub 2005 Oct 13. [PubMed:16224178 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
negative modulator
General Function:
Endopeptidase activity
Specific Function:
Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes. Important for defense against pathogens. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Can also promote apoptosis.
Gene Name:
CASP1
Uniprot ID:
P29466
Molecular Weight:
45158.215 Da
References
  1. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. [PubMed:10888929 ]
  2. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM: Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001 Jun;48(6):1393-9; discussion 1399-401. [PubMed:11383749 ]
  3. Vincent JA, Mohr S: Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007 Jan;56(1):224-30. [PubMed:17192486 ]
  4. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. [PubMed:18977395 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
negative modulator
General Function:
Phospholipase a2 activator activity
Specific Function:
Involved in the activation cascade of caspases responsible for apoptosis execution. At the onset of apoptosis it proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. Cleaves and activates caspa...
Gene Name:
CASP3
Uniprot ID:
P42574
Molecular Weight:
31607.58 Da
References
  1. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. [PubMed:10888929 ]
  2. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM: Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol. 2002 Jul;52(1):54-61. [PubMed:12112047 ]
  3. Dommergues MA, Plaisant F, Verney C, Gressens P: Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience. 2003;121(3):619-28. [PubMed:14568022 ]
  4. Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, Oh YJ, Markelonis GJ, Oh TH: Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma. 2003 Oct;20(10):1017-27. [PubMed:14588118 ]
  5. Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Seigel GM, Kelly ME: An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Mol Pharmacol. 2004 Nov;66(5):1113-22. Epub 2004 Aug 10. [PubMed:15304547 ]
  6. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. [PubMed:18977395 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
negative modulator
General Function:
Metal ion binding
Specific Function:
Electron carrier protein. The oxidized form of the cytochrome c heme group can accept an electron from the heme group of the cytochrome c1 subunit of cytochrome reductase. Cytochrome c then transfers this electron to the cytochrome oxidase complex, the final protein carrier in the mitochondrial electron-transport chain.Plays a role in apoptosis. Suppression of the anti-apoptotic members or acti...
Gene Name:
CYCS
Uniprot ID:
P99999
Molecular Weight:
11748.69 Da
References
  1. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002 May 2;417(6884):74-8. [PubMed:11986668 ]
  2. Matsuki S, Iuchi Y, Ikeda Y, Sasagawa I, Tomita Y, Fujii J: Suppression of cytochrome c release and apoptosis in testes with heat stress by minocycline. Biochem Biophys Res Commun. 2003 Dec 19;312(3):843-9. [PubMed:14680842 ]
  3. Chu HC, Lin YL, Sytwu HK, Lin SH, Liao CL, Chao YC: Effects of minocycline on Fas-mediated fulminant hepatitis in mice. Br J Pharmacol. 2005 Jan;144(2):275-82. [PubMed:15665864 ]
  4. Heo K, Cho YJ, Cho KJ, Kim HW, Kim HJ, Shin HY, Lee BI, Kim GW: Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice. Neurosci Lett. 2006 May 8;398(3):195-200. Epub 2006 Feb 15. [PubMed:16469440 ]
  5. Mansson R, Hansson MJ, Morota S, Uchino H, Ekdahl CT, Elmer E: Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. Neurobiol Dis. 2007 Jan;25(1):198-205. Epub 2006 Oct 24. [PubMed:17067803 ]
  6. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. [PubMed:18977395 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 01, 2016 02:26